Benchmark Raises Emergent BioSolutions (NYSE:EBS) Price Target to $12.00

Emergent BioSolutions (NYSE:EBS) had its price target hoisted by equities research analysts at Benchmark from $8.00 to $12.00 in a report issued on Thursday, Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Benchmark’s price target points to a potential downside of 2.44% from the company’s previous close.

Separately, Rodman & Renshaw reiterated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Up 33.7 %

EBS traded up $3.10 during midday trading on Thursday, reaching $12.30. 2,687,528 shares of the company were exchanged, compared to its average volume of 3,397,877. The company has a market cap of $650.79 million, a price-to-earnings ratio of -1.10 and a beta of 1.57. Emergent BioSolutions has a one year low of $1.42 and a one year high of $15.10. The company’s fifty day moving average price is $8.32 and its 200 day moving average price is $7.65. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. The company had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same quarter last year, the company posted ($1.06) EPS. As a group, analysts expect that Emergent BioSolutions will post -1.3 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EBS. Entropy Technologies LP purchased a new position in Emergent BioSolutions during the third quarter valued at approximately $155,000. PFG Investments LLC bought a new position in shares of Emergent BioSolutions in the third quarter worth $228,000. Assenagon Asset Management S.A. raised its position in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after buying an additional 316,700 shares in the last quarter. SeaCrest Wealth Management LLC boosted its stake in Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after buying an additional 3,705 shares during the period. Finally, SG Americas Securities LLC increased its stake in Emergent BioSolutions by 250.1% in the 3rd quarter. SG Americas Securities LLC now owns 60,724 shares of the biopharmaceutical company’s stock worth $507,000 after acquiring an additional 43,378 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.